

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/002389

International filing date: 07 March 2005 (07.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: DE  
Number: 10 2004 060 412.6  
Filing date: 14 December 2004 (14.12.2004)

Date of receipt at the International Bureau: 27 May 2005 (27.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**BUNDESREPUBLIK DEUTSCHLAND**

19.05.2005

**Prioritätsbescheinigung über die Einreichung  
einer Patentanmeldung**

**Aktenzeichen:** 10 2004 060 412.6

**Anmeldetag:** 14. Dezember 2004

**Anmelder/Inhaber:** KRKA tovarna zdravil, d.d., Nova Mesto/SI

**Bezeichnung:** Mixed solvate of olanzapine

**IPC:** noch nicht festgelegt

**Die angehefteten Stücke sind eine richtige und genaue Wiedergabe der ursprünglichen Unterlagen dieser Patentanmeldung.**

München, den 27. April 2005  
**Deutsches Patent- und Markenamt**  
**Der Präsident**  
Im Auftrag

  
Faust

# UEXKÜLL & STOLBERG

PATENTANWÄLTE

BESELERSTRASSE 4  
D-22607 HAMBURG

DR. J.-D. FRHR. von UEXKÜLL (-1992)  
DR. ULRICH GRAF STOLBERG (-1998)

## HAMBURG

EUROPEAN PATENT ATTORNEYS  
EUROPEAN TRADEMARK ATTORNEYS  
DIPL.-ING. JÜRGEN SUCHANTKE  
DIPL.-ING. ARNULF HUBER  
DR. ALLARD von KAMEKE  
DIPL.-BIOL. INGEBORG VOELKER  
DR. PETER FRANCK  
DR. GEORG BOTH  
DR. ULRICH-MARIA GROSS  
DR. HELMUT van HEESCH  
DR. JOHANNES AHME  
DR. HEINZ-PETER MUTH  
DR. MARTIN WEBER-QUITZAU  
DR. BERND JANSSEN  
DR. ALBRECHT von MENGES  
DR. MARTIN NOHLEN  
DR. PETER WIEGELEBEN  
DR. ANDERS von HOMEYER

## RECHTSANWÄLTE

DR. FRANK DETTMANN  
ASKAN DEUTSCH, LL.M.  
ATTORNEY-AT-LAW, NEW YORK

## MÜNCHEN

EUROPEAN PATENT ATTORNEYS  
EUROPEAN TRADEMARK ATTORNEYS  
DIPL.-ING. LARS MANKE  
Dr. OLGA BEZZUBOVA

December 2004

P 66970 UMG/FZ

KRKA, tovarna zdravil, d.d., Novo mesto  
Smarjeska cesta 6

SLO-8501 Novo mesto  
Slowenien

## Mixed solvate of olanzapine

### FIELD OF THE INVENTION

The present invention belongs to the field of organic chemistry and relates to a new mixed solvate form of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2,3-b] [1,5] benzodiazepine (hereinafter referred to by its generic name "olanzapine"), a process for its preparation and processes for the preparation of polymorphic form I of olanzapine.

### 10 BACKGROUND OF THE INVENTION

Olanzapine has shown to have high activity with regard to the central nervous system and is also useful for the treatment of schizophrenia, schizophreniform disorders, acute mania, mild anxiety states and psychosis.

Various polymorphic and pseudopolymorphic forms, such as solvates, of olanzapine have become known. Some of them are useful for conversion to other desirable forms.

5 The British patent GB 1 533 235 discloses antipsychotically effective thienobenzodiazepines by a generic formula which also covers olanzapine.

US patent 5,229,382 discloses olanzapine explicitly. The described process for its synthesis involves a crystallization from acetonitrile.

10 EP-B-733 635 claims crystalline form II olanzapine, and this polymorphic form is said to be more stable than the material obtained according to US 5,229,382 which is designated "form I olanzapine". Both the form I and the form II of olanzapine are characterized by e. g. X-ray data. The preparation of the  
15 more stable form II of olanzapine is effected by dissolving technical grade olanzapine in ethyl acetate and crystallization from the resulting solution by any conventional process such as seeding, cooling, scratching the glass of the reaction vessel or other common techniques.

20 WO 02/18390 discloses the monohydrate form I and the dihydrate form I of olanzapine, a process for production thereof and a process for production of form I of olanzapine which comprises the steps of stirring olanzapine monohydrate form I or crude olanzapine or form II of olanzapine in  
25 methylene chloride at reflux, cooling, filtering and drying. It is also described that a repeating of the process described in US 5,229,382 Example 1, subexample 4 did not lead to formation of form I of olanzapine.

30 WO 03/101997 relates to processes for preparation of form I of olanzapine by regulation of the pH-value of the solution.

WO 03/055438 discloses the preparation of form I olanzapine by crystallization from ethanol and subsequent conversion of the obtained ethanol solvate.

5 US patent 5,637,584 discloses the (mono)methylene chloride solvate form of olanzapine and a method for its conversion to the polymorphic form I of olanzapine.

10 EP-B-733 634 discloses three specific solvates of olanzapine, namely the methanol, ethanol and 1-propanol solvates and a process for production of form II olanzapine by drying such a solvate.

WO 03/097650 describes two new mixed solvate forms, the water/methylene chloride solvate and the water/DMSO solvate, methods for preparing them, and their transformation to polymorphic form I.

15 WO 2004/006933 discloses a process for the preparation of form I olanzapine, as well as various pseudopolymorphic forms, namely the isopropanol solvate, and the acetonitrile/methylene chloride/water and acetonitrile/water mixed solvates of olanzapine, and the polymorphic form A.

20 However, the prior art processes for preparation of form I olanzapine often do not lead to a satisfactory yield. Moreover, they result in olanzapine having a purity which is not satisfactory for the preparation of pharmaceutical formulations as impurities are present which are difficult to  
25 be removed. This is often caused by undesired impurities which are formed upon preparation of precursors and are therefore, upon conversion of the precursors to form I olanzapine, introduced in the final product.

Further, prior art processes often do not allow use of higher temperatures without impairing yield or purity of the form I olanzapine.

Consequently, there is still a need for improved processes to  
5 prepare purified olanzapine form I in a satisfactory yield.

Further, there is a need for precursors which allow the easy preparation of polymorphic forms of olanzapine or the conversion to other forms of olanzapine in a high purity.

These problems are solved by the present invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The invention relates to a water/isopropanol mixed solvate which contains 2 molecules of water and 1 molecule of isopropanol per 2 molecules of olanzapine.

15 The solvate according to the invention was subjected to an x-ray structure analysis. Single crystal x-ray diffraction data were collected at room temperature on a Nonius Kappa CCD diffractometer by means of the Nonius Collect Software. The structure was solved by using SIR97 (direct methods) and the  
20 refinement was performed with X'tal software. The crystallographic data for the olanzapine isopropanol/water mixed solvate, particularly the interplanar distances (a, b, c) and angles ( $\alpha$ ,  $\beta$ ,  $\gamma$ ), are indicated in Table 1.

25

Table 1

Space group	C2/c (No. 15)
a	24.55 Å
b	12.51 Å


c	15.31 Å
$\alpha$	90°
$\beta$	125.3°
$\gamma$	90°
R	0.059

Thus, the invention also relates to the isopropanol/water mixed solvate of olanzapine characterized by the x-ray structure shown in Figure 1. Figure 1 shows the ORTEP view of the asymmetric unit of the solvate according to the invention which corresponds to the formula  $C_{17}H_{20}N_4S \cdot H_2O \cdot \frac{1}{2}(C_3H_7OH)$ . It is to be noted the population of the disordered isopropanole molecule in Figure 1 is 0.50. Thus, an isopropanol molecule occurs only with every second molecule of olanzapine.

10 Further, the solvate according to the invention is characterized by a NMR spectrum in  $CDCl_3$  showing peaks at approximately 1.20 ppm, 2.20-2.40 ppm and 4.03 ppm. Preferably, the solvate is characterized by the NMR spectrum shown in Figure 2.

15 The NMR spectra were obtained using a Varian UNITY+ 300 (300 MHz) spectrometer and  $CDCl_3$  as solvent with tetramethylsilane as internal standard.

Figure 2 shows the NMR spectrum of the solvate according to the invention. The peaks were assigned as follows ( $^1H$  NMR; 20  $CDCl_3$ , 300 MHz):



. H<sub>2</sub>O . ½ (CH<sub>3</sub>)<sub>2</sub>CHOH

5

10

15

Chemical shift $\delta$	Assignment
1.20 (3H, d)	CH <sub>3</sub> - isopropanol
2.30 (3H, s)	4'-CH <sub>3</sub>
2.34 (3H, s)	2- CH <sub>3</sub>
2.20-2.40 (2H, br s)	H - water
2.49 (4H, m)	3'-CH <sub>2</sub>
3.52 (4H, m)	2'-CH <sub>2</sub>
4.03 (0.5H, dq)	CH - isopropanol
5.02 (H, broad s)	10-NH
6.29 (H, broad s)	3-CH
6.29-7.05 (4H, m)	6,7,8,9-H

20

The solvate according to the invention is prepared by a process which comprises crystallizing it from a solvent mixture comprising isopropanol and water in a ratio of at least 9 to 1, preferably at least 20 to 1 and most preferred at least 35 to 1 parts by volume.

25

It has been shown particularly advantageous if the crystallization is effected by adding the water to a solution comprising olanzapine and the isopropanol.

30

It has unexpectedly been found that the preparation of the olanzapine water-isopropanol mixed solvate can easily be accomplished if olanzapine is crystallized by using a solvent mixture which comprises isopropanol and water. In this way persistent impurities are removed from the active compound



and the dissolved olanzapine can also be recovered from filtrates in an easy manner.

The olanzapine used as a starting material for the preparation of the water/isopropanol mixed solvate according to the invention can be in any form, e.g. it can be used when it is contained in a reaction solution or in a filtrate in combination with other solvents, or it can be in crude, anhydrous or any solvated or hydrated form or a mixture thereof.

10 In a preferred embodiment, the water/isopropanol mixed solvate according to the invention is prepared from a reaction mixture. An example is given in the following.

For this purpose, a mixture of 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride and 1-methylpiperazine is heated in high boiling solvents, e.g. dimethylsulfoxide or toluene, or mixtures thereof, preferably under reflux, until the reaction is completed, preferably 3 to 12 hours. The solution is then cooled, preferably to temperatures ranging from 90°C to room temperature, and optionally a part of the reaction mixture is distilled off, preferably under vacuum, at temperatures ranging from room temperature to 90°C, preferably at 50°C to 90°C. To the obtained solution isopropanol and water are separately added in any order or a mixture thereof is added. Preferably, 25 isopropanol is added first, followed by the addition of water to initiate crystallization. Preferably, the clear solution is cooled to temperatures from boiling temperature to 10°C, and water is added to start crystallization. The product is then filtered off, washed with isopropanol, dried at room 30 temperature under vacuum to a constant weight, and the

water/isopropanol mixed solvate according to the invention is obtained.

5 In a further preferred embodiment, the water/isopropanol mixed solvate of olanzapine is prepared from mother liquors containing olanzapine and for example methylene chloride, or from a methylene chloride solvate form. An example is given in the following.

10 In such a case, the solvent is optionally distilled off, preferably under vacuum, and subsequently isopropanol and water are separately added in any order or a mixture thereof is added. Preferably, isopropanol is added first, followed by the addition of water to initiate crystallization. After the crystallization has been completed, the precipitate is filtered off and dried.

15 In a further preferred embodiment, the water/isopropanol mixed solvate is prepared from crude olanzapine, or from olanzapine in anhydrous or any solvated or hydrated form, or mixtures thereof. An example is given in the following.

20 In such a case, the olanzapine is dissolved by heating in a mixture of isopropanol and water, or in either isopropanol or water with the other solvent being subsequently added. The obtained clear solution is cooled to temperatures from boiling temperature to 10°C, and water is added to start crystallization. The product is then filtered off, washed  
25 with isopropanol, dried at room temperature under vacuum to a constant weight, and the water-isopropanol mixed solvate according to the invention is obtained.

The water-isopropanol mixed solvate obtained by any one of the above processes can optionally be recrystallized. During  
30 the crystallization or precipitation procedure of any

process, ethylenediaminetetraacetic acid disodium salt can be added and, after stirring, undissolved material be hot filtered.

5 The water-isopropanol mixed solvate according to the invention prepared by any of the above processes is of high quality and substantially free of impurities and is therefore ideally suited for the preparation of various other highly pure solvates, hydrates or anhydrous forms or mixtures thereof.

10 The water-isopropanol mixed solvate according to the invention is particularly useful for the preparation of olanzapine form I in a high purity.

Thus, the invention also relates to a process for the preparation of form I olanzapine, wherein the  
15 isopropanol/water mixed solvate of olanzapine according to the invention is used.

Form I of olanzapine is rather difficult to be prepared in substantially pure form, because formation of the thermodynamically more stable form II is favoured. According  
20 to the process of the present invention pure form I could be obtained which is in particular substantially free from form II and solvates.

In a preferred embodiment of the process, in a step (a) the isopropanol/water mixed solvate is converted to a methylene  
25 chloride solvate of olanzapine, and in a step (b) the methylene chloride solvate is converted to form I olanzapine.

It is advantageous if in step (a) a solution of the isopropanol/water mixed solvate in methylene chloride is

prepared, the solvent is partly evaporated and the remaining solution is cooled.

It is also preferred if in step (a) a solution of the isopropanol/water mixed solvate in methylene chloride is prepared, a drying agent is added to the solution, the drying agent is removed from the mixture and the methylene chloride solvate of olanzapine is recovered. Preferably, the mixture is stirred for some time and filtered, and finally, the product is recovered, e. g. by crystallization after cooling. A particularly useful drying agent is anhydrous  $\text{CaSO}_4$ .

In a further process for effecting step (a), the water-isopropanol mixed solvate according to the invention is suspended in methylene chloride and the suspension is heated until a clear solution is obtained. Then a part of the solvent is evaporated under vacuum or optionally at atmospheric pressure or a combination thereof at temperatures ranging from the boiling point of the solution to  $-30^\circ\text{C}$  to precipitate olanzapine methylene chloride solvate, which can be isolated by filtration. Alternatively, the heated solution can be cooled to temperatures from room temperature to  $-30^\circ\text{C}$  to precipitate the olanzapine methylene chloride solvate.

In another typical process for effecting step (a), the water-isopropanol mixed solvate is suspended in methylene chloride and the suspension is heated to  $35^\circ\text{C}$  to obtain a clear solution. Subsequently, a drying agent, preferably Drierite ( $\text{CaSO}_4$  anhydrous), is added, and the desired product is recovered in conventional manner.

Optionally, a seeding with higher amounts of crystalline methylene chloride solvate. Also olanzapine form I is a suitable seeding material.

It is preferred to use as methylene chloride solvate in step (b) the methylene chloride hemisolvate. For its preparation it is usually necessary to dry the product in a vacuum at room temperature for 2 to 12 hours.

5 In a typical and preferred process for effecting step (b), isopropanol is added to the prepared olanzapine methylene chloride solvate in a volume (l) by weight (kg) ratio of 5:1 to 2:1, preferably 3:1 to 2:1, and the obtained suspension is stirred at a temperature of 15°C to 35°C, in particular at  
10 room temperature, for 15 to 90 min, preferably from 30 to 60 min. Preferably, seeding with form I olanzapine can be used. The filtered product is dried under vacuum at a temperature from room temperature to 50°C until a constant weight is achieved.

15 In another typical and preferred process for effecting step (b), methylene chloride solvate is suspended in isopropanol at a weight (kg) by volume (l) ratio of 1:30 to 1:2, preferably 1:15 to 1:3, which has been presaturated with olanzapine. The obtained suspension is stirred at a  
20 temperature of 5°C to 50°C, in particular at room temperature, for 15 to 90 min, preferably from 30 to 60 min. The product is filtered off and dried under vacuum at a temperature ranging from room temperature to a constant weight, and then at 50°C to a constant weight. Form I  
25 olanzapine is isolated.

In another typical and preferred process for effecting step (b), methylene chloride solvate is first dried under vacuum at a temperature of 30 to 55°C for 6 to 36 hours. The obtained product is suspended in isopropanol at a weight (kg)  
30 by volume (l) ratio of 1:5 to 1:2, preferably 1:3 to 1:2. The obtained suspension is stirred at a temperature of 15°C to

35°C, in particular at room temperature, for 15 to 60 min, preferably from 15 to 30 min. The product is filtered off and dried under vacuum at room temperature to a constant weight, and then at 50°C to a constant weight. This process offers  
5 the advantage that it very much diminishes the possibility of formation of the undesired form II of olanzapine.

Further, the invention also relates to a process for the preparation of any other solvate or hydrate forms of olanzapine, or mixtures thereof, wherein the  
10 isopropanol/water mixed solvate of olanzapine according to the invention is used.

Moreover, the invention also relates to a process for the preparation of anhydrous forms of olanzapine, wherein the isopropanol/water mixed solvate of olanzapine according to  
15 the invention is used.

It has also surprisingly been found out that in the process of preparing form I olanzapine the purity of the final product can be influenced by the type of the materials which come into contact with the liquid media from which precursors or the final product is crystallized or precipitated. This  
20 has in particular been observed when using elevated temperatures in the process.

The invention therefore also relates to a process for preparing form I olanzapine wherein at least one of (a)  
25 precursors for olanzapine form I and (b) olanzapine form I is crystallized or precipitated from a liquid medium which medium is present in a container wherein the surfaces of the container contacting the medium are comprising at least one polymer, preferably are consisting of at least one polymer.

It was unexpectedly found out that such polymer surfaces in particular diminish the likelihood of formation of the undesired form II of olanzapine, especially when using elevated temperatures. This is very beneficial since the form II is an impurity which is very difficult to be removed, if possible at all, and even small amounts thereof may function as seeding crystals which lead to formation of further amounts of the undesired form II olanzapine.

It is preferred that the precursors and/or the olanzapine form I are prepared using the isopropanol/water mixed solvate according to the invention. This leads to highly pure olanzapine form I.

The liquid medium can be a solution or dispersion which upon crystallization or precipitation leads to form I olanzapine or a precursor of form I olanzapine.

Preferably, at least one crystallization or precipitation step of a precursor is carried out such that the liquid medium is contacting the mentioned polymer surface. It is particularly preferred that such a precursor is the methylene chloride hemisolvate of olanzapine. It was found out that in particular in the crystallization or precipitation of the methylene chloride hemisolvate the likelihood of formation of the undesired form II olanzapine is diminished if carried in contact with the polymer surfaces.

In an even further preferred embodiment, the methylene chloride hemisolvate has been prepared by using the very pure isopropanol/water mixed solvate according to the invention. This accomplishes the preparation of very pure olanzapine of form I.

The container can be any equipment, like a vessel or reactor, wherein a crystallization or precipitation occurs.

It has been proven particularly useful if the polymer contains fluorine. Preferred examples are selected from  
5 polytetrafluoroethylene, e.g. available under the brand Teflon, fluorinated ethylene propylene copolymer, perfluoro alkoxy polymer, or ethylene tetrafluoroethylene copolymer.

It is possible that only the surfaces contacting the liquid medium are comprising polymer or are consisting of polymer, but typically the whole container is made of polymer, preferably made of polytetrafluoroethylene.

The invention is in the following illustrated by means of examples.

15

#### Examples

#### **Preparation of the water-isopropanol mixed solvate of olanzapine**

##### 20 Example 1

A mixture of 4-amino-2-methyl-10H-thieno[2,3][1,5]benzodiazepine hydrochloride (26.6 g), 1-methylpiperazine (92 ml), dimethylsulfoxide (120 ml) and toluene (120 ml) was refluxed for 4 hours. The solution was cooled to 95°C and 200 ml were  
25 distilled off under vacuum. The residue was cooled to room temperature, isopropanol (180 ml) was added, and the solution was further cooled to 0°C and water (36 ml) was added to



initialize crystallization. After the crystallization was completed, the precipitate was filtered off and washed with isopropanol (20 ml). The wet product was suspended in isopropanol (200 ml) and heated to reflux to obtain a clear solution. Ethylenediaminetetraacetic acid disodium salt (3 g) was added and the suspension was stirred for one hour. Undissolved material was removed by hot filtration. The clear solution was cooled to 25°C and water (6 ml) was added to start crystallization. The suspension was cooled to 0°C and after completion of the crystallization the product was filtered off and washed with isopropanol (10 ml). The product was dried at room temperature under vacuum to a constant weight. Yield: 22.84 g. Loss on drying (140°C): 13.6%. Water content (Karl Fischer): 5.12%.

15

#### Example 2

A mixture of 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride (26.6 g), 1-methylpiperazine (92 ml), dimethylsulfoxide (36 ml) and toluene (120 ml) was refluxed for 4 hours. The solution was cooled to 95°C and 80 ml were distilled off under vacuum. The residue was cooled to room temperature, and isopropanol (180 ml) was added. The solution was further cooled to 0°C and water (36 ml) was added to initialize crystallization. After the crystallization was completed, the precipitate was filtered off and washed with isopropanol (20 ml). The wet product was suspended in isopropanol (200 ml) and heated to reflux to obtain a clear solution. Ethylenediaminetetraacetic acid disodium salt (3 g) was added and the suspension was stirred for one hour. Undissolved material was removed by hot filtration. The clear solution was cooled to 35 °C and water (6 ml) was added to

start crystallization. The suspension was cooled to 0°C, upon finalization of the crystallization, the product was filtered off and washed with isopropanol (10 ml). The product was dried at room temperature under vacuum to a constant weight.

5 Yield: 21.98 g. Loss on drying (140°C): 13.2 %. Water content (Karl Fischer): 5.09%. %. Assay of isopropanol (GC): 8.55 %.

### Example 3

10 A mixture of 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride (26.6 g), 1-methylpiperazine (92 ml), dimethylsulfoxide (36 ml) and toluene (120 ml) was refluxed for 4 hours. The solution was cooled to 95°C and 120 ml were distilled off under vacuum. The residue was cooled to room temperature, and isopropanol (180 ml) was added. The solution  
15 was further cooled to 0°C and water (36 ml) was added to initialize crystallization. After completion of the crystallization, the precipitate was filtered off and washed with isopropanol (20 ml). The wet product was suspended in isopropanol (200 ml) and heated to reflux to obtain a clear  
20 solution. Ethylenediaminetetraacetic acid disodium salt (3 g) was added and the suspension was stirred for one hour. Undissolved material was removed by hot filtration. The clear solution was cooled to 35°C and water (6 ml) was added to  
25 start crystallization. The suspension was cooled to 0°C, upon completion of the crystallization, the product was filtered off and washed with isopropanol (10 ml). The product was dried at room temperature under vacuum to a constant weight. Yield: 24.35 g. Loss on drying (140°C): 13.5%. Water content (Karl Fischer): 5.05%.

Example 4

Anhydrous olanzapine (10 g) was suspended in isopropanol (108 ml) and heated to reflux to obtain a clear solution. The solution was slowly cooled. Water (6 ml) was added at 57°C to start crystallization. The suspension was cooled to 0°C, upon finalization of the crystallization, the product was filtered off and washed with isopropanol (5 ml). The product was dried at room temperature under vacuum to a constant weight. Yield: 10.97 g. Loss on drying (140°C): 13.3%. Water content (Karl Fischer): 5.13%.

Example 5

60 g of olanzapine obtained from mother liquors was suspended in isopropanol (650 ml) and heated to reflux to obtain a clear solution. Ethylenediaminetetraacetic acid disodium salt (7.9 g) was added and the suspension was stirred for one hour. Undissolved material was removed by hot filtration. The clear solution was cooled to 25°C and water (16 ml) was added to start crystallization. The suspension was cooled to 0°C and, upon completion of the crystallization, the product was filtered off and washed with isopropanol (50 ml). The product was dried at room temperature under vacuum to a constant weight. Yield: 57.64 g. Loss on drying (140°C): 13.5%. Water content (Karl Fischer): 5.26%.

25

Example 6

The solution of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine (41.86 g, 0.11 mmol) (prepared according to WO 2004/065390), pyridinium p-

toluenesulfonate (55.29 g, 0.22 mmol) and sulfur (11.99 g, 0.374 mmol) in benzonitrile (1100 mL) was stirred at 140°C for 11 h, cooled to 90°C and concentrated to an oily residue. The residue was diluted with dichloromethane and isopropanol (250 mL, 1 : 1). The precipitate was filtered off and washed with dichloromethane and isopropanol (20 mL, 1 : 1). The filtrate was extracted with HCl (250 mL, 2 M). The organic phase was further extracted with HCl (2 X 100 mL, 1 M). The combined aqueous phases were cooled in an ice bath and made alkaline by using 5 M NaOH. The obtained turbid solution was left in a refrigerator over night resulting in a suspension. This was separated by filtration and washed with isopropanol (2 X 25 mL). The wet material was suspended in isopropanol (215 mL) and heated to reflux to obtain a clear solution. The solution was hot filtered. Water (6.5 mL) was added to induce crystallization. The obtained suspension was cooled to 0°C, and upon completion of crystallisation, the product was filtered off and washed with isopropanol (10 mL). The product was dried at room temperature under vacuum to a constant weight. Yield: 18.61 g. Loss on drying (140 °C): 12.8 %. Water content (Karl Fischer): 5.29 %.

#### 25 Example 7

The solution of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine (3.805 g, 10 mmol) (prepared according to WO 2004/065390), pyridinium p-toluenesulfonate (5.026 g, 20 mmol) and sulfur (1.122 g, 35 mmol) in benzonitrile (100 mL) was stirred at 140°C for 8.5 h, cooled to 90°C and concentrated to an oily residue. The residue was diluted with isopropanol (50 mL) and dimethyl

5 sulfoxide (5 mL). The precipitate was filtered off and washed with isopropanol (5 mL). Water (10 mL) and sodium hydroxide (1.00 g, 25 mmol) were added to the filtrate. The mixture was stirred at room temperature until the sodium hydroxide had dissolved. The turbid solution was left in a refrigerator over night resulting in a suspension. This was filtered off and washed with isopropanol (5 mL). The wet material was suspended in isopropanol (25 mL) and the suspension was heated to reflux. Then solids were hot filtered. Water (0.75 10 mL) was added to the filtrate to induce crystallization. The resulting suspension was cooled to 0°C, and upon completion of crystallisation, the product was filtered off and washed with isopropanol (1 mL). The product was then dried at room temperature under vacuum to a constant weight. Yield: 0.738 15 g.

### **Preparation of olanzapine methylene chloride hemisolvate**

#### Example 8

20 Water-isopropanol mixed solvate of olanzapine (11 g) was suspended in methylene chloride (132 ml) and heated to obtain a clear solution. 66 ml of the solvent was distilled off. Another 16 ml of methylene chloride was added and distilled off. The mixture was hot filtered and concentrated under vacuum to a volume of 36 ml. During vacuum destillation the 25 solution was cooled and the product precipitated. The product was filtered off and dried under vacuum at room temperature to a constant weight. Yield: 8.47 g. Loss on drying (140°C): 12.7 %. Water content (Karl Fischer): 0.40%.

#### 30 Example 9

Olanzapine water-isopropanol mixed solvate (30. g) was suspended in methylene chloride (330 ml) and heated to 35°C to obtain a clear solution. Drierite (CaSO<sub>4</sub> anhydrous, 45 g) was added and it was stirred for one hour. The suspension was  
5 hot filtered and concentrated under vacuum to a volume of 100 ml. During vacuum distillation the solution was cooled and the product precipitated. The product was filtered off and dried under vacuum at room temperature to a constant weight. Yield: 21.31 g. Loss on drying (140°C): 11.3%. Water content  
10 (Karl Fischer): 0.51%.

#### Example 10

Olanzapine water-isopropanol mixed solvate (25 g) was suspended in methylene chloride (300 ml) and heated to obtain  
15 a clear solution. The mixture was concentrated at 25 to 30°C under weak vacuum to 130 ml. The mixture was hot filtered and cooled to -20°C. The obtained suspension was filtered and the wet cake was dried under vacuum at room temperature to a constant weight. Yield: 17.7 g. Loss on drying (140°C):  
20 12.8%. Water content (Karl Fischer): 1.16%.

#### Example 11

Olanzapine water-isopropanol mixed solvate (30 g) was suspended in methylene chloride (360 ml) and the suspension  
25 was heated to obtain a clear solution. The solution was concentrated at 25 to 30°C under weak vacuum to 180 ml. The mixture was hot filtered into a reactor made from perfluorated polymer and evaporated to dryness at room temperature under vacuum. The residue was dried under vacuum

at room temperature to a constant weight. Yield: 27.5 g. Loss on drying (140°C): 12.6%. Water content (Karl Fischer): 0.41%.

5 Example 12

Olanzapine water-isopropanol mixed solvate (50 g) was suspended in methylene chloride (600 ml) and the suspension was heated to obtain a clear solution. The solution was concentrated at 25 to 30°C under a weak vacuum to 220 ml. The solution was then hot filtered and seeded with olanzapine form I. The suspension was cooled to -15°C and solids were filtered off. The obtained wet cake was dried under vacuum at room temperature to a constant weight. Yield: 36.15 g. Loss on drying (140°C): 12.7%. Water content (Karl Fischer): 0.57%.

**Preparation of olanzapine of form I**

In the following examples 13 to 17 olanzapine methylene chloride hemisolvate was used which has been prepared according to any one of examples 8 to 12 which employ use of the water-isopropanol mixed solvate of olanzapine according to the invention.

Example 13

25 Olanzapine methylene chloride hemisolvate (10 g) was suspended in isopropanol (20 ml). The suspension was stirred at room temperature for one hour. The product was filtered

off and dried under vacuum at room temperature to a constant weight, and then at 50°C to a constant weight. Yield: 7.8 g.

Example 14

5 Olanzapine methylene chloride hemisolvate (10 g) was suspended in isopropanol (150 ml, presaturated with olanzapine). The suspension was stirred at room temperature for one hour. The product was filtered off and dried under vacuum at room temperature to a constant weight, and then at 50°C to a constant weight. Yield: 14.3 g

Example 15

15 Olanzapine methylene chloride hemisolvate (6.00 g) was homogenized with olanzapine form I (0.30 g). The mixture was suspended in isopropanol (150 ml) and stirred at room temperature for 40 min. The suspension was filtered and the filter cake dried under vacuum at room temperature to a constant weight, and then at 50°C to a constant weight. Yield: 4.63 g.

Example 16

20  
25 Seeds of olanzapine form I were suspended in isopropanol (30 ml) and olanzapine methylene chloride hemisolvate (15 g) as well as isopropanol (7.5 ml) were added. The obtained suspension was stirred at room temperature for 30 min. The mixture was filtered and the separated solid was dried under vacuum at room temperature until a constant weight was achieved and then at 50°C to a constant weight. The yield was  
30 11.6 g.



Example 17

Olanzapine methylene chloride hemisolvate (20 g) was dried under vacuum at 50°C for 12 hours.

5

10 g of the dried material were suspended in isopropanol (25 ml) and the mixture was stirred at room temperature for 20 min. The mixture was filtered and the separated solid was dried under vacuum at room temperature until a constant

10

weight was achieved and then at 50°C to a constant weight.

The yield was 9 g.

Claims

1. Isopropanol/water mixed solvate of olanzapine which contains 2 molecules of water and 1 molecule of isopropanol per 2 molecules of olanzapine.  
5
2. Isopropanol/water mixed solvate of olanzapine characterized by the x-ray structure shown in Figure 1.
3. Isopropanol/water mixed solvate of olanzapine characterized by a NMR spectrum in CDCl<sub>3</sub> showing peaks at approximately 1.20 ppm, 2.20-2.40 ppm and 4.03 ppm.  
10
4. Isopropanol/water mixed solvate of olanzapine characterized by the NMR spectrum shown in Figure 2.
5. Process for the preparation of the isopropanol/water mixed solvate of olanzapine according to any one of claims 1 to 4, which comprises crystallizing it from a solvent mixture comprising isopropanol and water in a ratio of at least 9 to 1 parts by volume.  
15
6. Process according to claims 5, wherein the solvent mixture comprises isopropanol and water in a ratio of at least 20 to 1 parts by volume.  
20
7. Process according to claims 5 or 6, wherein the solvent mixture comprises isopropanol and water in a ratio of at least 35 to 1 parts by volume.
8. Process according to any one of claims 5 to 7, wherein the crystallization is effected by adding the water to a solution comprising olanzapine and the isopropanol.  
25

9. Process for the preparation of form I olanzapine, wherein the isopropanol/water mixed solvate according to any one of claims 1 to 4 is used.
10. Process according to claim 9, wherein
- 5 (a) the isopropanol/water mixed solvate is converted to a methylene chloride solvate of olanzapine, and
- (b) the methylene chloride solvate is converted to form I olanzapine.
- 10 11. Process according to claim 10, wherein in step (a) a solution of the isopropanol/water mixed solvate in methylene chloride is prepared, the solvent is partly evaporated and the remaining solution is cooled.
12. Process according to claim 10, wherein in step (a) a solution of the isopropanol/water mixed solvate in
- 15 methylene chloride is prepared, a drying agent is added to the solution, the drying agent is removed from the mixture and the methylene chloride solvate of olanzapine is recovered.
- 20 13. Process according to claim 12, wherein anhydrous  $\text{CaSO}_4$  is used as drying agent.
14. Process according to any one of claims 10 to 13, wherein the methylene chloride solvate is methylene chloride hemisolvate of olanzapine.
- 25 15. Process according to any one of claims 10 to 14, wherein in step (b) the methylene chloride solvate is suspended in isopropanol.

16. Process according to claim 15, wherein the ratio between methylene chloride solvate (kg) and isopropanol (l) is 1:5 to 1:2.

5 17. Process according to any one of claims 10 to 16, wherein in step (b)

methylene chloride hemisolvate is dried under vacuum at a temperature of 30 to 55°C for 6 to 36 hours,

the dried hemisolvate is suspended in isopropanol,

10 the suspension is stirred at a temperature of 15 to 35°C for 15 to 60 min, and

the form I olanzapine is separated.

18. Process for the preparation of any other solvate or hydrate forms of olanzapine, or mixtures thereof, wherein the isopropanol/water mixed solvate of olanzapine  
15 according to any one of claims 1 to 4 is used.

19. Process for the preparation of anhydrous forms of olanzapine, wherein the isopropanol/water mixed solvate of olanzapine according to any one of claims 1 to 4 is used.

20 20. Use of the isopropanol/water mixed solvate of olanzapine according to any one of claims 1 to 4 for the preparation of any other solvate or hydrate forms of olanzapine, or mixtures thereof, or for the preparation of anhydrous forms of olanzapine.

25 21. Process for preparing form I olanzapine wherein at least one of (a) a precursor for olanzapine form I and (b) olanzapine form I is crystallized or precipitated from a liquid medium which medium is present in a container

wherein the surfaces of the container contacting the medium are comprising at least one polymer.

22. Process according to claim 21 wherein a precursor for olanzapine from I is crystallized or precipitated.
- 5 23. Process according to claim 22, wherein the precursor is methylene chloride hemisolvate of olanzapine.
24. Process according to any one of claims 21 to 24, wherein the precursor or the olanzapine form I has been prepared using the isopropanol/water mixed solvate according to any one of claims 1 to 4.
25. Process according to any one of claims 21 to 24, wherein the surfaces of the container contacting the medium are consisting of at least one polymer.
26. Process according to any one of claims 21 to 25, wherein  
15 the polymer contains fluorine.
27. Process according to claim 26, wherein the polymer is selected from polytetrafluoroethylene, fluorinated ethylen propylene copolymer, perfluor alkoxy polymer, or ethylene terafluoroethylene copolymer.

## Abstract

The invention relates to a novel and well defined solvate form of olanzapine which contains 2 molecules of water and 1 molecule of isopropanol per 2 molecules of olanzapine, and which can be converted into other forms of olanzapine, in particular form I of olanzapine, as well as processes for preparing form I olanzapine.

5

10

15

20

Figure 1




Figure-2

